Dr. Meghan Drummond, PhD, has joined the CMT Research Foundation as vice president of research and drug development. She will lead the Foundation’s research and drug development strategy, overseeing the advancement of promising therapeutic approaches for Charcot-Marie-Tooth disease.
In her new role, Dr. Drummond will manage CMTRF’s scientific portfolio from discovery through translational development, collaborate with the Scientific Advisory Board, Research Advisory Council and research partners and identify strategic opportunities to accelerate treatments for the CMT community.
Dr. Drummond reports to CMTRF CEO Laura M. MacNeill. Reporting to Dr. Drummond will be Dr. Kate Andersh, PhD, the Foundation’s scientific portfolio manager.
“I’m excited to join the CMT Research Foundation because of its unwavering commitment to transforming scientific discoveries into real treatments,” said Dr. Drummond. “This is a pivotal moment for CMT research and drug development, with new technologies and insights opening unprecedented opportunities. My goal is to focus our resources on the most promising therapeutic strategies, build strong collaborations across the scientific and patient communities, and accelerate innovation into the clinic for those who need it the most.”
Dr. Drummond brings more than 15 years of experience bridging basic science, translational research and industry-driven drug development, with a deep commitment to patient-centered innovation.
She joins CMTRF from Regeneron Pharmaceuticals, where she established and led the Auditory Sciences Therapeutic Focus Area, guiding programs from early discovery through clinical development. She spearheaded the company’s first gene therapy for hereditary hearing loss, now in clinical trials, and expanded it into a multi-indication genetic medicines platform. In this role, she directed cross-functional teams translating genetic discoveries into therapeutic candidates and oversaw the scientific integration of Decibel Therapeutics’ R&D portfolio following its acquisition.
“We are thrilled to welcome Dr. Drummond to the Foundation,” said Laura M. MacNeill, CEO. “Her expertise in genetic medicine and proven track record in advancing therapies from discovery to clinical development will strengthen our ability to strategically invest in research that accelerates treatments and brings real hope to the CMT community.”
Dr. Drummond earned her doctorate in human genetics from Michigan State University, where she studied the molecular basis of hereditary hearing loss. She completed a postdoctoral fellowship at the National Institutes of Health focused on the genetics and molecular pathogenesis of sensory disorders. She currently resides in New York.